FY2026 EPS Forecast for Kodiak Sciences Lowered by Analyst

Kodiak Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut Kodiak Sciences’ FY2026 EPS forecast to a loss of $3.91 per share from $3.75, while maintaining a Buy rating and a $126 price target. Its estimates project a return to profitability in FY2029.
  • Analyst sentiment is broadly positive but mixed: MarketBeat reports a Moderate Buy consensus and an average price target of $109, with six Buy, one Hold, and one Sell rating.
  • Kodiak reported quarterly EPS of ($1.05), slightly better than the consensus loss estimate of ($1.06). Insiders purchased about 2.19 million shares worth $181.3 million over the prior 90 days.
  • Five stocks we like better than Kodiak Sciences.

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Analysts at HC Wainwright lowered their FY2026 EPS estimates for Kodiak Sciences in a note issued to investors on Monday, November 16th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($3.91) per share for the year, down from their prior estimate of ($3.75). HC Wainwright currently has a "Buy" rating and a $126.00 price target on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.97) per share. HC Wainwright also issued estimates for Kodiak Sciences' FY2027 earnings at ($3.52) EPS, FY2028 earnings at ($1.27) EPS, FY2029 earnings at $1.76 EPS and FY2030 earnings at $6.09 EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($1.05) EPS for the quarter, topping analysts' consensus estimates of ($1.06) by $0.01.

Several other equities analysts have also commented on the stock. The Goldman Sachs Group started coverage on shares of Kodiak Sciences in a report on Wednesday, September 30th. They issued a "neutral" rating and a $103.00 price objective on the stock. UBS Group lifted their price objective on Kodiak Sciences from $120.00 to $150.00 and gave the company a "buy" rating in a research note on Friday, November 13th. JPMorgan Chase & Co. boosted their price objective on Kodiak Sciences from $56.00 to $66.00 and gave the company an "overweight" rating in a report on Monday, August 3rd. Weiss Ratings lowered Kodiak Sciences from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, October 6th. Finally, Lifesci Capital increased their target price on Kodiak Sciences from $85.00 to $145.00 and gave the stock an "outperform" rating in a research note on Monday, September 28th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $109.00.

Read Our Latest Analysis on KOD

Kodiak Sciences Price Performance

Kodiak Sciences stock opened at $96.80 on Wednesday. The firm has a 50 day simple moving average of $79.26 and a 200-day simple moving average of $46.48. The stock has a market cap of $6.33 billion, a price-to-earnings ratio of -23.73 and a beta of 2.02. Kodiak Sciences has a 1-year low of $18.15 and a 1-year high of $112.79.

Insider Activity

In related news, Director Bros. Advisors Lp Baker acquired 86,432 shares of Kodiak Sciences stock in a transaction dated Thursday, November 5th. The shares were acquired at an average cost of $98.51 per share, for a total transaction of $8,514,416.32. Following the completion of the purchase, the director owned 20,424,859 shares in the company, valued at approximately $2,012,052,860.09. The trade was a 0.42% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired 2,188,845 shares of company stock valued at $181,326,862 in the last 90 days. 44.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kodiak Sciences

Several large investors have recently bought and sold shares of the stock. Bank of America Corp DE acquired a new position in shares of Kodiak Sciences in the 2nd quarter valued at $14,949,000. Bank of New York Mellon Corp acquired a new stake in Kodiak Sciences during the 2nd quarter worth $4,361,000. Squarepoint Ops LLC lifted its position in Kodiak Sciences by 112.6% in the second quarter. Squarepoint Ops LLC now owns 151,098 shares of the company's stock valued at $5,887,000 after acquiring an additional 80,042 shares during the last quarter. Algert Global LLC lifted its position in Kodiak Sciences by 26.1% in the second quarter. Algert Global LLC now owns 186,476 shares of the company's stock valued at $7,265,000 after acquiring an additional 38,546 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Kodiak Sciences by 31.8% in the first quarter. The Manufacturers Life Insurance Company now owns 120,629 shares of the company's stock valued at $4,598,000 after acquiring an additional 29,121 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Kodiak Sciences Company Profile

(Get Free Report)

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company's research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak's technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.

See Also

Earnings History and Estimates for Kodiak Sciences (NASDAQ:KOD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Kodiak Sciences Right Now?

Before you consider Kodiak Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.

While Kodiak Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines